New regulatory routes for cancer treatment in Britain
We're pleased to launch new and informative webpages that will help you navigate the new research regulatory landscape.
Over the past year the ECMC Programme Office has been working with regulators to produce a paper that translates the post Brexit processes for obtaining regulatory approval and advice. The authors group had representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), The Association of the British Pharmaceutical Industry (ABPI), The Accelerated Access Collaborative (AAC) and Independent Cancer Patients' Voice (ICPV). We all understood the difficulties researchers were likely to encounter in the new world and the paper has drawn on the authors combined expertise to provide advice and step by step guidance on how to approach and work with regulators. We hope that you find the paper and the associated webpages a helpful resource in planning your next research project.